Abstract：Objective To observe the effects of recombinant fusion protein interleukin (IL)-18 on the expression of immune-inflammatory factors in the mice infected with Staphylococcus aureus (SA), and to investigate the mechanism of action of IL-18 in defense of SA infection in vivo. Methods A total of 40 specific pathogen-free female BLAB/c mice were randomly divided into four groups:control, SA infection, immunized, and intervention. A mouse model of SA infection was established by nasal inoculation with SA liquid. The immunized group and the intervention group were intranasally given IL-18 before SA modeling, and then the SA infection group and the intervention group received the nasal inoculation with SA liquid; the control group was treated with phosphate buffered saline instead. The levels of IL-4, interferon (IFN)-γ, tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), IgM in the serum and bronchoalveolar lavage fluid (BALF) of mice were measured by enzyme-linked immunosorbent assay. The expression of macrophage inflammatory protein (MIP)-1α mRNA and MIP-2β mRNA in the lung tissue of mice were determined by real-time fluorescent quantitative PCR. Results Compared with the control group, the SA infection group and the immunized group had significantly higher levels of IL-4, G-CSF, and IgM in the serum and BALF and expression of MIP-1α mRNA and MIP-2β mRNA in the lung tissue (P < 0.05); the SA infection group had a significantly lower level of IFN-γ and a significantly higher level of TNF in the serum and BALF (P < 0.05); the immunized group had a significantly higher level of IFN-γ in the serum and BALF (P < 0.05). Compared with the SA infection group, the intervention group had significantly higher levels of IL-4, IFN-γ, G-CSF, and IgM in the serum and BALF and expression of MIP-1α mRNA in the lung tissue. In contrast, the intervention group showed a significantly lower level of TNF in the serum and BALF and expression of MIP-2β mRNA in the lung tissue (P < 0.05). All the above indicators in the intervention group were significantly higher than those in the control group (P < 0.05), except the serum level of IFN-γ. Conclusions In the mice infected with SA, the recombinant fusion protein IL-18 by mucosal immunity can affect inflammatory factors in the serum and BALF and the expression of MIP-1α mRNA and MIP-2β mRNA in the lung tissue to promote the anti-infective immune response and enhance the ability to clear pathogens.
CHEN Chen,CHEN Qiang,LI Lan et al. Effects of recombinant fusion protein interleukin-18 on expression of immune-inflammatory factors in mice infected with Staphylococcus aureus[J]. CJCP, 2017, 19(6): 705-711.
Chambers HF, Deleo FR. Waves of resistance:Staphylococcus aureus in the antibiotic era[J]. Nat Rev Microbiol, 2009, 7(9):629-641.
[2]
Seil JT, Webster TJ. Antimicrobial applications of nanotechnology:methods and literature[J]. Int J Nanomedicine, 2012, 7:2767-2781.
[3]
Peterson PK, Verhoef J, Sabath LD, et al. Effect of protein A on staphylococcal opsonization[J]. Infect Immun, 1977, 15(3):760-764.
[4]
Cunnion KM, Zhang HM, Frank MM. Availability of complement bound to Staphylococcus aureus to interact with membrane complement receptors influences efficiency of phagocytosis[J]. Infect Immun, 2003, 71(2):656-662.
[5]
Cunnion KM, Lee JC, Frank MM. Capsule production and growth phase influence binding of complement to Staphylococcus aureus[J]. Infect Immun, 2001, 69(11):6796-6803.
[6]
Kitur K, Parker D, Nieto P, et al. Toxin-induced necroptosis is a major mechanism of Staphylococcus aureus lung damage[J]. PLoS Pathog, 2015, 11(4):e1004820.
[7]
de Haas CJ, Veldkamp KE, Peschel A, et al. Chemotaxis inhibitory protein of Staphylococcus aureus, a bacterial antiinflammatory agent[J]. J Exp Med, 2004, 199(5):687-695.
Liu CI, Liu GY, Song Y, et al. A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulence[J]. Science, 2008, 319(5868):1391-1394.
[10]
Tuchscherr L, Medina E, Hussain M, et al. Staphylococcus aureus phenotype switching:an effective bacterial strategy to escape host immune response and establish a chronic infection[J]. EMBO Mol Med, 2011, 3(3):129-141.
[11]
Kinoshita M, Shinomiya N, Ono S, et al. Restoration of natural IgM production from liver B cells by exogenous IL-18 improves the survival of burn-injured mice infected with Pseudomonas aeruginosa[J]. J Immunol, 2006, 177(7):4627-4635.
[12]
Kuranaga N, Kinoshita M, Kawabata T, et al. Interleukin-18 protects splenectomized mice from lethal Streptococcus pneumoniae sepsis independent of interferon-gamma by inducing IgM production[J]. J Infect Dis, 2006, 194(7):993-1002.
[13]
Qiao Y, Ning X, Chen Q, et al. Clinical and molecular characteristics of invasive community-acquired Staphylococcus aureus infections in Chinese children[J]. BMC Infect Dis, 2014, 14:582.
Wertheim HF, Melles DC, Vos MC, et al. The role of nasal carriage in Staphylococcus aureus infections[J]. Lancet Infect Dis, 2005, 5(12):751-762.
[16]
Bogaert D, van Belkum A, Sluijter M, et al. Colonisation by Streptococcus pneumoniae and Staphylococcus aureus in healthy children[J]. Lancet, 2004, 363(9424):1871-1872.
[17]
Morel JC, Park CC, Kumar P, et al. Interleukin-18 induces rheumatoid arthritis synovial fibroblast CXC chemokine production through NFkappaB activation[J]. Lab Invest, 2001, 81(10):1371-1383.
[18]
Yoshimoto T, Tsutsui H, Tominaga K. IL-18, although antiallergic when administered with IL-12, stimulates IL-4 and histamine released by basophils[J]. Proc Natl Acad Sci U S A, 1999, 96(24):13962-13966.
[19]
Kang DH, Weaver MT. Airway cytokine responses to acute and repeated stress in a murine model of allergic asthma[J]. Bio Psychol, 2010, 84(1):66-73.
[20]
Truyen E, Coteur L, Dilissen E, et al. Evaluation of airway inflammation by quantitative Th1/Th2 cytokine mRNA measurement in sputum of asthma patients[J]. Thorax, 2006, 61(3):202-208.
[21]
Pagès F, Lazar V, Berger A, et al. Analysis of interleukin-18, interleukin-1 converting enzyme (ICE) and interleukin-18-related cytokines in Crohn's disease lesions[J]. Eur Cytokine Netw, 2001, 12(1):97-104.
[22]
Enoksson, SL, Grasset EK, Hägglöf T, et al. The inflammatory cytokine IL-18 induces self-reactive innate antibody responses regulated by natural killer T cells[J]. Proc Natl Acad Sci U S A, 2011, 108(51):E1399-E1407.
[23]
Lorente JA, Marshall JC. Neutralization of tumor necrosis factor in preclinical models of sepsis[J]. Shock, 2005, 24 Suppl 1:107-119.
[24]
Fournier B, Philpott DJ. Recognition of Staphylococcus aureus by the innate immune system[J]. Clin Microbiol Rev, 2005, 18(3):521-540.
[25]
Gómez MI, Lee A, Reddy B, et al. Staphylococcus aureus protein A induces airway epithelial inflammatory responses by activating TNFR1[J]. Nat Med, 2004, 10(8):842-848.
[26]
Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis[J]. N Engl Med, 2003, 348(2):138-150.
[27]
Fei Y, Wang W, Kwiecinski J, et al. The combination of a tumor necrosis factor inhibitor and antibiotic alleviates staphylococcal arthritis and sepsis in mice[J]. J Infect Dis, 2011, 204(3):348-357.
[28]
Biet F, Locht C, Kremer L. Immunoregulatory functions of interleukin 18 and its role in defense against bacterial pathogens[J]. J Mol Med (Berl), 2002, 80(3):147-162.
[29]
Lomas-Neira JL, Chung CS, Wesche DE, et al. In vivo gene silencing (with siRNA) of pulmonary expression of MIP-2 versus KC results in divergent effects on hemorrhage-induced, neutrophil-mediated septic acute lung injury[J]. J Leukoc Biol, 2005, 77(6):846-853.
[30]
Semerad CL, Christopher MJ, Liu F, et al. G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow[J]. Blood, 2005, 106(9):3020-3027.
[31]
Dallaire F, Ouellet N, Bergeron Y, et al. Microbiological and inflammatory factors associated with the development of pneumococcal pneumonia[J]. J Infect Dis, 2001, 184(3):292-300.
[32]
Rijneveld AW, van den Dobbelsteen GP, Florquin S, et al. Roles of interleukin-6 and macrophage inflammatory protein-2 in pneumolysin-induced lung inflammation in mice[J]. J Infect Dis, 2002, 185(1):123-126.
